Neuroblastoma: Biology, Prognosis, and Treatment

Hematology/Oncology Clinics of North America

Volumn 24, Issue 1, 2010, Pages 65-86

  Park, Julie R ^a   Eggert, Angelika ^b   Caron, Huib ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Epidemiology; Neuroblastoma; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GANGLIOSIDE ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 2; ISOTRETINOIN; MYELOABLATIVE AGENT; NERVE GROWTH FACTOR; NEUROTROPHIN 3; NEUROTROPHIN 3 RECEPTOR; PROTEIN TYROSINE KINASE A; TOPOTECAN;

AGE; ALLELE; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER STEM CELL; CANCER SURGERY; CARCINOGENESIS; CHILDHOOD CANCER; CLINICAL FEATURE; CLINICAL TRIAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GANGLIONEUROMA; GENE AMPLIFICATION; GENETIC GAIN; GENETIC PREDISPOSITION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; NEUROBIOLOGY; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

CHILD; HUMANS; NEUROBLASTOMA; PROGNOSIS; RISK ASSESSMENT; TREATMENT FAILURE;

EID: 74749088219     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.11.011     Document Type: Review

References (125)

1. Stiller C.A., and Parkin D.M. International variations in the incidence of neuroblastoma. Int J Cancer 52 4 (1992) 538-543
2. Kushner B.H., Gilbert F., and Helson L. Familial neuroblastoma: case reports, literature review, and etiologic considerations. Cancer 57 9 (1986) 1887-1893
3. Belson M., Kingsley B., and Holmes A. Risk factors for acute leukemia in children: a review. Environ Health Perspect 115 1 (2007) 138-145
4. Connelly J.M., and Malkin M.G. Environmental risk factors for brain tumors. Curr Neurol Neurosci Rep 7 3 (May 2007) 208-214
5. Yamamoto K., Hayashi Y., Hanada R., et al. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. J Clin Oncol 13 8 (1995) 2033-2038
6. Kaneko Y., Kanda N., Maseki N., et al. Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: a chromosome and N-myc amplification study. J Clin Oncol 8 12 (1990) 2005-2013
7. Schilling F.H., Spix C., Berthold F., et al. Neuroblastoma screening at one year of age. N Engl J Med 346 14 (2002) 1047-1053
8. Woods W.G., Gao R.N., Shuster J.J., et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 346 14 (2002) 1041-1046
9. Clausen N., Andersson P., and Tommerup N. Familial occurrence of neuroblastoma, von Recklinghausen's neurofibromatosis, Hirschsprung's agangliosis and jaw-winking syndrome. Acta Paediatr Scand 78 5 (1989) 736-741
10. Rohrer T., Trachsel D., Engelcke G., et al. Congenital central hypoventilation syndrome associated with Hirschsprung's disease and neuroblastoma: case of multiple neurocristopathies. Pediatr Pulmonol 33 1 (2002) 71-76
11. Trochet D., O'Brien L.M., Gozal D., et al. PHOX2B genotype allows for prediction of tumor risk in congenital central hypoventilation syndrome. Am J Hum Genet 76 3 (2005) 421-426
12. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3 3 (2003) 203-216
13. Trochet D., Bourdeaut F., Janoueix-Lerosey I., et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet 74 4 (2004) 761-764
14. van Limpt V., Schramm A., van Lakeman A., et al. The Phox2B homeobox gene is mutated in sporadic neuroblastomas. Oncogene 23 57 (2004) 9280-9288
15. Longo L., Panza E., Schena F., et al. Genetic predisposition to familial neuroblastoma: identification of two novel genomic regions at 2p and 12p. Hum Hered 63 3-4 (2007) 205-211
16. Chen Y., Takita J., Choi Y.L., et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455 (2008) 971-974
17. George R.E., Sanda T., Hanna M., et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455 (2008) 975-978
18. Janoueix-Lerosey I., Lequin D., Brugières L., et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455 (2008) 967-970
19. Mossé Y.P., Laudenslager M., Longo L., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455 (2008) 930-935
20. Triche T.J. Neuroblastoma: biology confronts nosology. Arch Pathol Lab Med 110 11 (1986) 994-996
21. Mosse Y.P., Laudenslager M., Khazi D., et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 75 4 (2004) 727-730
22. O'Brien C.A., Pollett A., Gallinger S., et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445 7123 (2007) 106-110
23. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 432 7015 (2004) 396-401
24. Tirode F., Laud-Duval K., Prieur A., et al. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11 5 (2007) 421-429
25. Allenspach E.J., Maillard I., Aster J.C., et al. Notch signaling in cancer. Cancer Biol Ther 1 5 (2002) 466-476
26. Blanc E., Goldschneider D., Douc-Rasy S., et al. Wnt-5a gene expression in malignant human neuroblasts. Cancer Letters 228 1-2 (2005) 117-123
27. Taipale J., and Beachy P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature 411 6835 (2001) 349-354
28. Russell D., and Rubinstein L. Pathology of tumours of the nervous system (1989), Edward Arnold, London
29. Beckwith J., and Perrin E. In situ neuroblastomas: a contribution to the natural history of neural crest tumors. Am J Pathol 43 (1963) 1089-1104
30. Shimada H., Ambros I.M., Dehner L.P., et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86 2 (1999) 364-372
31. Shimada H., Chatten J., Newton Jr. W., et al. Histophatologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglineuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73 (1984) 405-416
32. Peuchmaur M., d'Amore E.S., Joshi V.V., et al. Revision of the international neuroblastoma pathology classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 98 10 (2003) 2274-2281
33. de Bernardi B., Rogers D., Carli M., et al. Localized neuroblastoma: surgical and pathologic staging. Cancer 60 5 (1987) 1066-1072
34. Haas-Kogan D.A., Swift P.S., Selch M., et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys 56 1 (2003) 28-39
35. Evans A.E., Chatten J., D'Angio G.J., et al. A review of 17 IV-S neuroblastoma patients at the Children's Hospital of Philadelphia. Cancer 45 5 (1980) 833-839
36. Brodeur G.M., Pritchard J., Berthold F., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11 8 (1993) 1466-1477
37. Brodeur G.M., Seeger R.C., Barrett A., et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6 12 (1988) 1874-1881
38. Messina J.A., Cheng S.C., Franc B.L., et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 47 7 (2006) 865-874
39. Castleberry R.P., Shuster J.J., and Smith E.I. The pediatric oncology group experience with the international staging system criteria for neuroblastoma. Member Institutions of the Pediatric Oncology Group. J Clin Oncol 12 11 (1994) 2378-2381
40. Haase G.M., Atkinson J.B., Stram D.O., et al. Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the international staging systems. J Pediatr Surg 30 2 (1995) 289-294 [discussion: 295]
41. Cecchetto G., Mosseri V., De Bernardi B., et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 23 33 (2005) 8483-8489
42. Cohn S.L., Pearson A.D., London W.B., et al. The international Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27 (2009) 289-297
43. Monclair T., Brodeur G.M., Ambros P.F., et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force Report. J Clin Oncol 27 (2009) 298-303
44. Breslow N., and McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 31 12 (1971) 2098-2103
45. Evans A.E. Staging and treatment of neuroblastoma. Cancer 45 Suppl 7 (1980) 1799-1802
46. London W.B., Castleberry R.P., Matthay K.K., et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 23 27 (2005) 6459-6465
47. George R.E., London W.B., Cohn S.L., et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 23 27 (2005) 6466-6473
48. Schmidt M.L., Lal A., Seeger R.C., et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 23 27 (2005) 6474-6480
49. Park J, Villablanca J, Seeger R, et al. Favorable outcome of high risk (HR) stage 3 neuroblastoma (NB) with myeloablative therapy and 13-cis-retinoic acid. Presented at the 41st Annual Meeting of American Society of Oncology. Orlando, Florida, May 13-17, 2005.
50. Shimada H., Stram D.O., Chatten J., et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 87 19 (1995) 1470-1476
51. Maris J.M. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 17 1 (2005) 7-13
52. Riley R.D., Heney D., Jones D.R., et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 10 1 Pt 1 (2004) 4-12
53. Westermann F., and Schwab M. Genetic parameters of neuroblastomas. Cancer Lett 184 2 (2002) 127-147
54. Bown N., Cotterill S., Lastowska M., et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340 25 (1999) 1954-1961
55. Caron H., van Sluis P., de Kraker J., et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 334 4 (1996) 225-230
56. Attiyeh E.F., London W.B., Mosse Y.P., et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353 21 (2005) 2243-2253
57. Maris J.M., Hogarty M.D., Bagatell R., et al. Neuroblastoma. Lancet 369 9579 (2007) 2106-2120
58. Nakagawara A., Azar C.G., Scavarda N.J., et al. Expression and function of Trk-B and BDNF in human neuroblastomas. Mol Cell Biol 14 (1994) 759-767
59. Nakagawara A., Arima-Nakagawara M., Scavarda N.J., et al. Association between high levels of expression of the Trk gene and favorable outcome in human neuroblastomas. N Engl J Med 328 (1993) 847-854
60. Combaret V., Gross N., Lasset C., et al. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma. Eur J Cancer 33 12 (1997) 2101-2105
61. Borrello M.G., Bongarzone I., Pierotti M.A., et al. TRK and RET protooncogene expression in human neuroblastoma specimens: high frequency of Trk expression in non-advanced stages. Int J Cancer 54 (1993) 540-545
62. Kogner P., Barbany G., Dominici C., et al. Coexpression of messenger RNA for Trk protooncogene and low affinity nerve growth factor receptor in neuroblastomas with favorable prognosis. Cancer Res 53 (1993) 2044-2050
63. Suzuki T., Bogenmann E., Shimada H., et al. Lack of high affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 85 (1993) 377-384
64. Aoyama M., Asai K., Shishikura T., et al. Human neuroblastomas with unfavorable biologies express high levels of brain-derived neurotrophic factor mRNA and a variety of its variants. Cancer Lett 164 1 (2001) 51-60
65. Eggert A., Grotzer M.A., Ikegaki N., et al. Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res 62 6 (2002) 1802-1808
66. Eggert A., Ikegaki N., Kwiatkowski J., et al. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6 (2000) 1900-1908
67. van Limpt V., Chan A., Schramm A., et al. Phox2B mutations and the Delta-Notch pathway in neuroblastoma. Cancer Lett 228 1-2 (2005) 59-63
68. Ho R., Eggert A., Hishiki T., et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 62 22 (2002) 6462-6466
69. Barbacid M. The trk family of neurotrophin receptors. J Neurobiol 25 (1994) 1386-1403
70. Biffo S., Offenhauser N., Carter B.D., et al. Selective binding and internalisation by truncated receptors restrict the availability of BDNF during development. Development 121 8 (1995) 2461-2470
71. Eide F.F., Vining E.R., Eide B.L., et al. Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J Neurosci 16 10 (1996) 3123-3129
72. Haapasalo A., Koponen E., Hoppe E., et al. Truncated trkB.T1 is dominant negative inhibitor of trkB.TK+-mediated cell survival. Biochem Biophys Res Commun 280 5 (2001) 1352-1358
73. Brodeur G.M., Nakagawara A., Yamashiro D., et al. Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neurooncol 31 (1997) 49-55
74. Tacconelli A., Farina A.R., Cappabianca L., et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 6 4 (2004) 347-360
75. Castle V.P., Heidelberger K.P., Bromberg J., et al. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol 143 6 (1993) 1543-1550
76. Eggert A., Grotzer M.A., Zuzak T.J., et al. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 61 4 (2001) 1314-1319
77. Hopkins-Donaldson S., Bodmer J.L., Bourloud K.B., et al. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 60 16 (2000) 4315-4319
78. Teitz T., Wei T., Valentine M.B., et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6 5 (2000) 529-535
79. van Noesel M.M., van Bezouw S., Salomons G.S., et al. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 62 7 (2002) 2157-2161
80. Chan H.S., Haddad G., Thorner P.S., et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325 23 (1991) 1608-1614
81. Goldstein L.J., Fojo A.T., Ueda K., et al. Expression of the multidrug resistance, MDR1, gene in neuroblastomas. J Clin Oncol 8 1 (1990) 128-136
82. Haber M., Smith J., Bordow S.B., et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 24 10 (2006) 1546-1553
83. Norris M.D., Bordow S.B., Marshall G.M., et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334 4 (1996) 231-238
84. Jaboin J., Kim C.J., Kaplan D.R., et al. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway. Cancer Res 62 22 (2002) 6756-6763
85. Scala S., Wosikowski K., Giannakakou P., et al. Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Cancer Res 56 (1996) 3737-3742
86. Meitar D., Crawford S.E., Rademaker A.W., et al. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 14 (1996) 405-414
87. Almgren M.A., Henriksson K.C., Fujimoto J., et al. Nucleoside diphosphate kinase A/nm23-H1 promotes metastasis of NB69-derived human neuroblastoma. Mol Cancer Res 2 7 (2004) 387-394
88. Chantrain C.F., Shimada H., Jodele S., et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 64 5 (2004) 1675-1686
89. Gross N., Balmas Bourloud K., and Brognara C.B. MYCN-related suppression of functional CD44 expression enhances tumorigenic properties of human neuroblastoma cells. Exp Cell Res 260 2 (2000) 396-403
90. Jodele S., Chantrain C.F., Blavier L., et al. The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res 65 8 (2005) 3200-3208
91. Alvarado C.S., London W.B., Look A.T., et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol 22 3 (2000) 197-205
92. Perez C.A., Matthay K.K., Atkinson J.B., et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol 18 1 (2000) 18-26
93. Simon T., Spitz R., Faldum A., et al. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 26 12 (2004) 791-796
94. Simon T., Spitz R., Hero B., et al. Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q. Cancer Lett 237 2 (2006) 215-222
95. Strother DR, London W, Schmidt ML, et al. Surgery alone or followed by chemotherapy for patients with stages 2A and 2B neuroblastoma: results of Children's Oncology Group Study P9641. Presented at the 12th meeting of Advances in Neuroblastoma Research. Los Angeles, May 18-20, 2006.
96. D'Angio G.J., Evans A.E., and Koop C.E. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1 7708 (1971) 1046-1049
97. Nickerson H.J., Matthay K.K., Seeger R.C., et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 18 3 (2000) 477-486
98. Katzenstein H.M., Bowman L.C., Brodeur G.M., et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience-a pediatric oncology group study. J Clin Oncol 16 6 (1998) 2007-2017
99. Matthay K.K., Perez C., Seeger R.C., et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol 16 4 (1998) 1256-1264
100. Schmidt M.L., Lukens J.N., Seeger R.C., et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group study. J Clin Oncol 18 6 (Mar 2000) 1260-1268
101. Baker DL, Schmidt ML, Cohn SL, et al. A phase III trial of biologically-based therapy reduction for intermediate risk neuroblastoma. Presented at the 43rd Annual meeting of the American Society of Clinical Oncology. Chicago, June 2-6, 2007.
102. Kushner B.H., Cheung N.K., LaQuaglia M.P., et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol 14 2 (1996) 373-381
103. Hero B, Thorsten S, Benz-Bohm G, et al. Is a "wait and see" strategy justified in localised neuroblastoma in infancy? Presented at the 12th meeting of Advances in Neuroblastoma Research. Los Angeles, May 18-20, 2006.
104. Matthay K.K., Villablanca J.G., Seeger R.C., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341 16 (1999) 1165-1173
105. Kushner B.H., LaQuaglia M.P., Bonilla M.A., et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 12 12 (1994) 2607-2613
106. Valteau-Couanet D., Michon J., Boneu A., et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol 23 3 (2005) 532-540
107. Kreissman SG, Villablanca JG, Diller L, et al. Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma: a Children's Oncology Group study. Presented at the 43rd Annual meeting of the American Society of Clinical Oncology. Chicago, June 2-6, 2007.
108. Frantz C.N., London W.B., Diller L., et al. Recurrent neuroblastoma: randomized treatment with topotecan + cyclophosphamide (T + C) vs. topotecan alone(T). A POG/CCG Intergroup Study. J Clin Oncol 22 14S (2004) 8512
109. Park JR, Stewart CF, London W, et al. Targeted topotecan during induction therapy of high risk neuroblastoma: a Children's Oncology Group pilot study. Presented at the 42nd annual meeting of the American Society of Clinical Oncology. Atlanta, Georgia, June 2-6, 2006.
110. Adkins E.S., Sawin R., Gerbing R.B., et al. Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. J Pediatr Surg 39 6 (2004) 931-936
111. Brodeur G.M., and Maris J.M. Neuroblastoma. 4th edition (2002), Lippincott, Philadelphia
112. Kushner B.H., Wolden S., LaQuaglia M.P., et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol 19 11 (2001) 2821-2828
113. Bradfield S.M., Douglas J.G., Hawkins D.S., et al. Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma. Cancer 100 6 (2004) 1268-1275
114. Simon T., Bongartz R., Hero B., et al. Intensified external beam radiation therapy improves the outcome of stage 4 neuroblastoma in children >1 year with residual local disease. [abstract: 314]. Advances in Neuroblastoma Research (2006)
115. Berthold F., Boos J., Burdach S., et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 6 9 (2005) 649-658
116. Pritchard J., Cotterill S.J., Germond S.M., et al. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 44 4 (2005) 348-357
117. George R.E., Li S., Medeiros-Nancarrow C., et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 24 18 (2006) 2891-2896
118. Albertini M.R., Gan J., Jaeger P., et al. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. J Immunother Emphasis Tumor Immunol 19 4 (1996) 278-295
119. Hank J.A., Surfus J., Gan J., et al. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 15 1 (1994) 29-37
120. Yu A.L., Gilman A.L., Ozkaynak M.F., et al. A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following does intensive chemotherapy for high-risk neuroblastoma: Children's Oncology Group (COG) study ANBL0032 [abstract]. J Clin Oncol 27 (2009) 10067z
121. Roberts K.B. Cerebellar ataxia and "occult neuroblastoma" without opsoclonus. Pediatrics 56 3 (1975) 464-465
122. Altman A.J., and Baehner R.L. Favorable prognosis for survival in children with coincident opso-myoclonus and neuroblastoma. Cancer 37 2 (1976) 846-852
123. Matthay K.K., Blaes F., Hero B., et al. Opsoclonus myoclonus syndrome in neuroblastoma: a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy. Cancer Lett 228 1-2 (2005) 275-282
124. Scheibel E., Rechnitzer C., Fahrenkrug J., et al. Vasoactive intestinal polypeptide (VIP) in children with neural crest tumours. Acta Paediatr Scand 71 5 (1982) 721-725
125. El Shafie M., Samuel D., Klippel C.H., et al. Intractable diarrhea in children with VIP-secreting ganglioneuroblastomas. J Pediatr Surg 18 1 (1983) 34-36